Mostrar el registro sencillo del ítem
dc.contributor.author | Moreno, L. | |
dc.contributor.author | Lopez-Urbina, M.T. | |
dc.contributor.author | Farias, C. | |
dc.contributor.author | Domingue, G. | |
dc.contributor.author | Donadeu, M. | |
dc.contributor.author | Dungu, B. | |
dc.contributor.author | García Lescano, Héctor Hugo | |
dc.contributor.author | Gomez-Puerta, L.A. | |
dc.contributor.author | Lanusse, C. | |
dc.contributor.author | Gonzalez Zariquiey, Armando Emiliano | |
dc.date.accessioned | 2022-01-18T19:26:46Z | |
dc.date.available | 2022-01-18T19:26:46Z | |
dc.date.issued | 2012 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12866/10857 | |
dc.description.abstract | Oxfendazole (OFZ) is efficacious for porcine cysticercosis at 30mg/kg. OFZ is not registered to be used at this dose. The assessment of the OFZ and metabolites [(fenbendazole sulphone (FBZSO2), fenbendazole (FBZ)] plasma pharmacokinetic and tissue residue profiles after its oral administration to pigs and the withdrawal period for human consumption were reported. Forty-eight pigs allocated into two groups received OFZ (30mg/kg) orally as a commercial (CF) or as experimental formulation (SMF). Samples (blood, muscle, liver, kidney and fat) were collected over 30days post-treatment and analyzed by HPLC. OFZ was the main compound recovered in plasma, followed by FBZSO2 and low FBZ concentrations. OFZ AUC0-LOQ (209.9±33.9μg·h/ml) and Cmax (5.40±0.65μg/ml) parameters for the CF tended to be higher than those for the SMF (AUC0-LOQ: 159.4±18.3μgh/ml, Cmax: 3.80±0.35μg/ml). The highest total residue (OFZ+FBZSO2+FBZ) concentrations were quantified in liver, followed by kidney, muscle and fat tissue. FBZSO2 residue levels were the highest found in muscle (0.68±0.39μg/g) and fat (0.69±0.39μg/g). In liver and kidney the highest residues corresponded to FBZ (5.29±4.36μg/g) and OFZ (2.86±0.75μg/g), respectively. A withdrawal time of 17days post-treatment was established before tissues are delivered for human consumption. | en_US |
dc.language.iso | eng | |
dc.publisher | Elsevier | |
dc.relation.ispartofseries | Food and Chemical Toxicology | |
dc.rights | info:eu-repo/semantics/restrictedAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es | |
dc.subject | Male | en_US |
dc.subject | Controlled Study | en_US |
dc.subject | Animal Experiment | en_US |
dc.subject | Food Intake | en_US |
dc.subject | Blood Sampling | en_US |
dc.subject | Anthelmintics | en_US |
dc.subject | Cysticercosis | en_US |
dc.subject | Swine Diseases | en_US |
dc.subject | Benzimidazoles | en_US |
dc.subject | Dose-Response Relationship Drug | en_US |
dc.subject | Area Under Curve | en_US |
dc.subject | High Performance Liquid Chromatography | en_US |
dc.subject | Liver | en_US |
dc.subject | Kidney | en_US |
dc.subject | Adipose Tissue | en_US |
dc.subject | Drug Residues | en_US |
dc.subject | Fenbendazole Sulphone | en_US |
dc.subject | |Pharmacokinetics | en_US |
dc.title | A high oxfendazole dose to control porcine cysticercosis: Pharmacokinetics and tissue residue profiles | en_US |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | https://doi.org/10.1016/j.fct.2012.07.023 | |
dc.subject.ocde | https://purl.org/pe-repo/ocde/ford#3.01.07 | |
dc.relation.issn | 1873-6351 |
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |